News
Semaglutide and Bone Loss in Women: Menopause Risk
Semaglutide accelerates bone loss in postmenopausal women by combining weight loss with estrogen deficiency. Research shows 1-4% annual BMD decline. Mitigation includes protein optimization, resistance training, and targeted peptide adjuncts.
Semaglutide and Bone Loss in Women: Menopause Risk
Semaglutide accelerates bone loss in postmenopausal women by combining weight loss with estrogen deficiency. Research shows 1-4% annual BMD decline. Mitigation includes protein optimization, resistance training, and targeted peptide adjuncts.